Casirivimab and Imdevimab (REGN10933 and REGN10987)

Status
To Patients
Condition
COVID-19
Intervention Type
Intravenous (IV) Injection
Funder Type
Industry

Drug Details

Casirivimab and imdevimab are recombinant human IgG1 monoclonal antibodies that target the receptor binding domain of the spike protein of SARS-CoV-2. They are investigational drugs and are not approved for any indication. 

More Information

On November 21, 2020, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19. This includes those who are 65 years of age or older or who have certain chronic medical conditions.

www.REGENCOV2.com

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >